Test Compendium is your definitive resource for detailed information on a wide array of diagnostic tests. Each entry in our compendium is meticulously cataloged to aid healthcare providers in selecting and interpreting the right tests for their patients.
Displaying 376 - 400 of 475
Concurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline) Methodology Molecular Test Description Disease Solid tumors; Breast cancer, Ovarian cancer,
Concurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue Methodology Molecular Test Description Disease Solid tumorsOn Tissue: siPortfolio Multi-Omics™ • NGS (500+ genes, TMB, MSI)
LymphoSight™ Test Description Probes/Genes IHC/CISH ALK1, BCL-1, BCL-2, BCL-6, BRAF, Bob1, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20, CD21, CD23, CD25*, CD30, CD43, CD79a, CD138, C-MYC, EBV-LMP, Granzyme B, ICOS*, IgA, IgG, IgG4, IgM, Kappa, Ki-67, Lambda, LEF1*, Mum1, OCT2, Pax5, Perforin, PD-1, TIA1. *: Pending CISH: EBER, Kappa,
IgD Alternative Name Immunoglobulin D Methodology Immunohistochemistry (IHC) Test Description Probes/Genes IGD IHC Disease Aiding in the classification of lymphomas (marginal zone, mantle zone) and multiple
IgG Alternative Name Immunoglobulin G Methodology Immunohistochemistry (IHC) Test Description Probes/Genes IGG IHC Disease Classification of lymphomas and multiple myelomaIgG antibody reacts with surface
IgG4 Alternative Name Immunoglobulin G4 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes IGG4 IHC Disease IgG4 related sclerosing diseasesIdentification of IgG4-positive plasma cells
IgM Alternative Name Immunoglobulin M Methodology Immunohistochemistry (IHC) Test Description Probes/Genes IGM IHC Disease Aiding in the classification of lymphomas and multiple myelomaIgM antibody reacts
Inhibin Methodology Immunohistochemistry (IHC) Test Description Probes/Genes INHIBI IHC Disease Sex-cord stromal tumors, including Sertoli cell tumors, Leydig cell tumors , adrenocortical tumors, placental
Iron Alternative Name Prussian Blue Iron, Ferric Iron Methodology Special Stains Test Description Probes/Genes FE SS Disease Hemochromatosis, hemosiderosis and chromophobe renal cell carcinomaThe iron
Lysozyme Methodology Immunohistochemistry (IHC) Test Description Probes/Genes LYSO IHC Disease Acute myelomonocytic leukemia (M4), acute monocytic leukemia (M5)Also called muramidase Histiocytic enzyme
Kappa (IHC) Alternative Name Kappa Light Chain by IHC Methodology Immunohistochemistry (IHC) Test Description Probes/Genes KAPPA IHC Disease Monoclonality in malignant plasmacytic or lymphoid populations,
Ki-67 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes KI-67 IP Disease Used to help differentiate between benign versus malignant and increasingly used to grade various tumors (e.g.
Ki-67 (MIB-1) Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MIB1 IHC Disease Used to help differentiate between benign versus malignant and increasingly used to grade various tumors
KRAS by IHC Methodology Immunohistochemistry (IHC) Test Description Probes/Genes KRAS IHC Disease Pancreatic and colorectal cancer, Non-small cell lung cancer & ductal carcinoma of the pancreas, cardiofaciocutaneous
Lambda (IHC) Alternative Name Lambda Light Chain IgG Methodology Immunohistochemistry (IHC) Test Description Probes/Genes LAMBDA IHC Disease Restricted expression of either kappa or lambda suggests monoclonality
Mammaglobin Methodology Immunohistochemistry (IHC) Test Description Probes/Genes Mamma IHC Disease Breast cancersBelongs to the family of small epithelial secretory proteins (secretoglobins) of the uteroglobin/Clara
Melan A (Mart-1) Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MART1 IHC Disease Melanocytic tumors, and metastatic melanomasMelanocyte specific cytoplasmic protein involved in the
MiTF-1 Alternative Name Microphthalmia Transcription Factor Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MiTF IHC Disease Marker of melanocytic differentiation or melanin synthesis
MLH-1 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MSI Disease Lynch SyndromeA mismatch repair protein alongside MSH2, MSH6 and PMS2. Tumor screening test for all newly diagnosed
MOC31 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MOC31 IHC Disease Cholangiocarcinoma, liver metastases, lung adenocarcinoma, invasive ductal carcinoma of the breast, and invasive
MPO Alternative Name Myeloperoxidase Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MYELOP IHC Disease Detection of myeloid cellsMyeloperoxidase (MPO) is a major constituent of cytoplasmic
MSH-2 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MSI Disease Lynch syndrome, Muir-Torre syndrome, and sporadic colorectal cancerOne of the main genes of the Mismatch Repair family
MSH-6 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MSI Disease Colorectal cancer in patients with Lynch syndrome:The MSH6 gene on chromosome 2 is part of the DNA mismatch repair
MUC1 Alternative Name Mucin 1 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MUC1 IHC Disease Breast, pancreatic, lung, prostate, and ovarian cancer.Mucin-1 (MUC1) is a transmembrane
MUM-1 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MUM1 IHC Disease Subclassification of diffuse large B cell lymphoma (DLBCL) into germinal center B cell-like subtype and nongerminal
MYC ab. Methodology Immunohistochemistry (IHC) Test Description Probes/Genes MYC ab. Disease Burkitt Lymphoma and High-Grade B-Cell LymphomaThe Myc tag, derived from the c-Myc protein, is a popular epitope
Napsin-A Methodology Immunohistochemistry (IHC) Test Description Probes/Genes NAPSIN IHC Disease Distinguish adenocarcinomas from other forms of lung cancer.A novel aspartic proteinase of the pepsin family
NSE Alternative Name Neuron Specific Enolase Methodology Immunohistochemistry (IHC) Test Description Probes/Genes NSE IHC Disease Small cell lung carcinoma, carcinoids, islet cell tumors and neuroblastomas,
With core values rooted in service and integrity, our leadership team sets the bar high.
We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).
We also hold select state licensure where required.